

Contents

1. Introduction	1
2. Good practices in the manufacture of pharmaceutical products	2
3. Guidelines on inspection of pharmaceutical manufacturers	2
4. The WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce	2
5. Quality assurance of pharmaceutical and biological products manufactured by recombinant DNA technology	4
6. <i>The international pharmacopoeia</i> and related activities	4
6.1 Quality specifications for drug substances and dosage forms	4
6.2 Validation of analytical procedures	4
6.3 Simple test methodology	5
6.4 National laboratories for drug surveillance and control	5
6.5 Quality control of products derived from medicinal plants	5
7. International Chemical Reference Substances and International Infrared Reference Spectra	6
7.1 Establishment of reference substances	6
7.2 Infrared reference spectra	7
8. Stability of dosage forms	7
9. Extemporaneous preparations	8
9.1 Topical dosage forms	8
9.2 The local small-scale preparation of ophthalmic (eye) drops	8
10. Training of regulators	9
11. Arrangements for independent analysis of drug samples	9
Acknowledgements	10
References	12
Annex 1	
Good manufacturing practices for pharmaceutical products	14
Annex 2	
Provisional guidelines on the inspection of pharmaceutical manufacturers	80
Annex 3	
Proposed guidelines for implementation of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce	92
Annex 4	
Guidelines for assuring the quality of pharmaceutical and biological products prepared by recombinant DNA technology	105

Annex 5	
Validation of analytical procedures used in the examination of pharmaceutical materials	117
Annex 6	
List of available International Chemical Reference Substances	122
Annex 7	
List of adopted International Infrared Reference Spectra	127
Annex 8	
Study on the quality of selected drugs at the point of use in developing countries	128